• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
External validation of the number of risk factors score in a palliative care outpatient clinic at a comprehensive cancer center.综合癌症中心姑息治疗门诊中风险因素评分数量的外部验证
J Palliat Med. 2014 Jul;17(7):797-802. doi: 10.1089/jpm.2013.0256. Epub 2014 May 28.
2
Validation of a predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic.针对在门诊姑息性放疗诊所就诊的转移性癌症患者生存预测模型的验证。
Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):280-7. doi: 10.1016/j.ijrobp.2008.03.019.
3
Predictive model for survival in patients with advanced cancer.晚期癌症患者生存的预测模型。
J Clin Oncol. 2008 Dec 20;26(36):5863-9. doi: 10.1200/JCO.2008.17.1363. Epub 2008 Nov 17.
4
Factors affecting survival in 37 consecutive patients undergoing de novo stereotactic radiosurgery for contiguous sites of vertebral body metastasis from renal cell carcinoma.影响 37 例连续行初发立体定向放射外科治疗肾细胞癌椎体转移连续部位患者生存的因素。
J Neurosurg Spine. 2015 Jan;22(1):52-9. doi: 10.3171/2014.9.SPINE1482.
5
Impact of outpatient palliative care (PC) on symptom burden in patients with advanced cancer at a tertiary cancer center in Jordan.约旦一家三级癌症中心门诊姑息治疗对晚期癌症患者症状负担的影响。
Support Care Cancer. 2017 Jan;25(1):177-183. doi: 10.1007/s00520-016-3395-8. Epub 2016 Sep 7.
6
Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care.姑息性预后评分在晚期癌症患者中的成功验证。意大利多中心姑息治疗研究组
J Pain Symptom Manage. 1999 Apr;17(4):240-7. doi: 10.1016/s0885-3924(98)00146-8.
7
Assessment of the integration between oncology and palliative care in advanced stage cancer patients.晚期癌症患者肿瘤学与姑息治疗整合情况的评估
Support Care Cancer. 2017 Jun;25(6):1837-1843. doi: 10.1007/s00520-017-3588-9. Epub 2017 Jan 24.
8
A predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic.针对在门诊姑息性放疗诊所就诊的转移性癌症患者生存情况的预测模型。
Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1291-302. doi: 10.1016/s0360-3016(02)02832-8.
9
Diagnostic accuracy of the palliative prognostic score in hospitalized patients with advanced cancer.姑息性预后评分对晚期癌症住院患者的诊断准确性。
J Clin Oncol. 2004 Dec 1;22(23):4823-8. doi: 10.1200/JCO.2004.12.056.
10
A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care.一种新的姑息性预后评分:晚期癌症患者分期的第一步。意大利多中心姑息治疗研究组
J Pain Symptom Manage. 1999 Apr;17(4):231-9. doi: 10.1016/s0885-3924(98)00145-6.

引用本文的文献

1
Predicting the survival of patients with painful tumours treated with palliative radiotherapy: a secondary analysis using the 3-variable number-of-risk-factors model.预测接受姑息性放疗的疼痛性肿瘤患者的生存率:使用三变量风险因素数量模型的二次分析
Radiat Oncol. 2024 Oct 1;19(1):133. doi: 10.1186/s13014-024-02503-9.
2
Prediction of post-radiotherapy survival for bone metastases: a comparison of the 3-variable number of risk factors model with the new Katagiri scoring system.预测放疗后骨转移的生存情况:三种危险因素评分模型与新的片桐评分系统的比较。
J Radiat Res. 2022 Mar 17;63(2):303-311. doi: 10.1093/jrr/rrab121.
3
A phenomenological three-parameter model for predicting the extent of outpatient palliative care.一种用于预测门诊姑息治疗范围的现象学三参数模型。
Mol Clin Oncol. 2021 Sep;15(3):194. doi: 10.3892/mco.2021.2356. Epub 2021 Jul 21.
4
Multidisciplinary Prognostication Using the Palliative Prognostic Score in an Australian Cancer Center.
Palliat Care. 2015 Aug 2;9:7-14. doi: 10.4137/PCRT.S24411. eCollection 2015.

本文引用的文献

1
Modeling the longitudinal transitions of performance status in cancer outpatients: time to discuss palliative care.建模癌症门诊患者的体能状态纵向转变:讨论姑息治疗的时机。
J Pain Symptom Manage. 2013 Apr;45(4):726-34. doi: 10.1016/j.jpainsymman.2012.03.014. Epub 2012 Aug 30.
2
Prognostic indices for older adults: a systematic review.老年人预后指标的系统评价。
JAMA. 2012 Jan 11;307(2):182-92. doi: 10.1001/jama.2011.1966.
3
Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer.早期姑息治疗对转移性非小细胞肺癌患者化疗使用和临终关怀的影响。
J Clin Oncol. 2012 Feb 1;30(4):394-400. doi: 10.1200/JCO.2011.35.7996. Epub 2011 Dec 27.
4
Development of prognosis in palliative care study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study.姑息治疗研究预后(PiPS)预测模型的开发,以改善晚期癌症的预后:前瞻性队列研究。
BMJ. 2011 Aug 25;343:d4920. doi: 10.1136/bmj.d4920.
5
Early palliative care for patients with metastatic non-small-cell lung cancer.转移性非小细胞肺癌患者的早期姑息治疗。
N Engl J Med. 2010 Aug 19;363(8):733-42. doi: 10.1056/NEJMoa1000678.
6
Predictive model for survival in patients with advanced cancer.晚期癌症患者生存的预测模型。
J Clin Oncol. 2008 Dec 20;26(36):5863-9. doi: 10.1200/JCO.2008.17.1363. Epub 2008 Nov 17.
7
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.化疗联合支持治疗可提高晚期非小细胞肺癌患者的生存率:一项对16项随机对照试验个体患者数据的系统评价和荟萃分析。
J Clin Oncol. 2008 Oct 1;26(28):4617-25. doi: 10.1200/JCO.2008.17.7162. Epub 2008 Aug 4.
8
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.转移性乳腺癌每周一次与每三周一次紫杉醇治疗的随机III期试验,所有HER-2过表达患者均接受曲妥珠单抗治疗,HER-2非过表达患者随机分配接受或不接受曲妥珠单抗治疗:癌症与白血病B组方案9840的最终结果
J Clin Oncol. 2008 Apr 1;26(10):1642-9. doi: 10.1200/JCO.2007.11.6699.
9
Palliative medicine review: prognostication.姑息医学综述:预后评估
J Palliat Med. 2008 Jan-Feb;11(1):84-103. doi: 10.1089/jpm.2008.9992.
10
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.多西他赛联合泼尼松或米托蒽醌联合泼尼松治疗晚期前列腺癌:TAX 327研究的生存数据更新
J Clin Oncol. 2008 Jan 10;26(2):242-5. doi: 10.1200/JCO.2007.12.4008.

综合癌症中心姑息治疗门诊中风险因素评分数量的外部验证

External validation of the number of risk factors score in a palliative care outpatient clinic at a comprehensive cancer center.

作者信息

Glare Paul, Shariff Imran, Thaler Howard T

机构信息

1 Pain and Palliative Care Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center , New York, New York.

出版信息

J Palliat Med. 2014 Jul;17(7):797-802. doi: 10.1089/jpm.2013.0256. Epub 2014 May 28.

DOI:10.1089/jpm.2013.0256
PMID:24871990
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4518880/
Abstract

BACKGROUND

Prognostic tools are available to predict if terminally ill cancer patients have days or weeks to live. Tools for predicting the prognosis in ambulatory patients at an earlier stage are lacking. The Number of Risk Factors (NRF) score developed in ambulatory cancer patients receiving palliative radiation therapy may be suitable for this purpose but has not been tested in a palliative care setting.

OBJECTIVE

Our aim was to evaluate the prognostic accuracy of the NRF score in patients referred to a palliative care outpatient clinic at a comprehensive cancer center.

METHODS

We conducted a retrospective chart review of NRF scores and survival in 300 consecutive, newly referred patients. Measurements included primary cancer type, extent of disease, Karnofsky Performance Scale (KPS) score, and survival duration after first visit. One point was allocated each for cancer other than breast cancer, metastases other than bone, and low KPS score.

RESULTS

Of 300 patients, 236 (79%) had advanced disease. Of those 236, 212 (90%) had a cancer other than breast cancer, 180 (76%) had metastatic disease in sites other than bone, and 64 (27%) had a KPS score <70%. During the 2-year follow-up, 221 (94%) patients died, with overall median survival of 4.9 months (95% confidence interval, 3.9-6.1 months). NRF scores of 0 to 1, 2, and 3 split the sample into subgroups with highly significantly different survival among the groups, with medians 9.0, 4.6, and 2.1 months, respectively (Wilcoxon test χ(2)=43.9, degrees of freedom [df] 2, p<0.0001). A simple parametric model was fit to determine the probability of subgroup members surviving to a certain number of months.

CONCLUSIONS

In cancer patients referred to palliative care earlier in their disease trajectory, the NRF score may be a useful prognostic tool. Further validation in other palliative care populations is needed.

摘要

背景

已有预后工具可预测晚期癌症患者还剩几天或几周的生命。但缺乏用于预测早期门诊患者预后的工具。在接受姑息性放射治疗的门诊癌症患者中开发的风险因素数量(NRF)评分可能适用于此目的,但尚未在姑息治疗环境中进行测试。

目的

我们的目的是评估NRF评分在综合癌症中心姑息治疗门诊转诊患者中的预后准确性。

方法

我们对300例连续新转诊患者的NRF评分和生存情况进行了回顾性病历审查。测量指标包括原发癌类型、疾病范围、卡氏功能状态量表(KPS)评分以及首次就诊后的生存时间。非乳腺癌、非骨转移和低KPS评分各得1分。

结果

300例患者中,236例(79%)患有晚期疾病。在这236例患者中,212例(90%)患有非乳腺癌,180例(76%)在非骨部位有转移性疾病,64例(27%)的KPS评分<70%。在2年的随访期间,221例(94%)患者死亡,总体中位生存期为4.9个月(95%置信区间,3.9 - 6.1个月)。NRF评分为0至1分、2分和3分将样本分为亚组,各组间生存情况差异极显著,中位数分别为9.0个月、4.6个月和2.1个月(Wilcoxon检验χ(2)=43.9,自由度[df]为2,p<0.0001)。拟合了一个简单的参数模型来确定亚组成员存活至特定月数的概率。

结论

对于在疾病进程中较早转诊至姑息治疗的癌症患者,NRF评分可能是一种有用的预后工具。需要在其他姑息治疗人群中进一步验证。